Even as Lancet published the results of Phase-1 and Phase-2 clinical trial data of the Sputnik V vaccine — cleared by Moscow regulators for public use — the Russian research institute has now submitted “comprehensive data” on the vaccine’s safety and efficacy to Indian authorities, The Indian Express has learnt.
Senior officials said India had sought this from the Moscow-based Gamaleya Research Institute of Epidemiology and Microbiology. The vaccine candidate triggered a “strong” immune response in Phases 1 & 2 of the clinical trials…